PD-1 Inhibition Minimally Affects Cisplatin-Induced Toxicities in a Murine Model

Katie Spielbauer, Lisa Cunningham, Nicole Schmitt

Research output: Contribution to journalArticle

Abstract

Immune checkpoint inhibition used in combination with standard cisplatin-based chemotherapy regimens is currently under evaluation in clinical trials for head and neck squamous cell carcinoma (HNSCC). The impact of anti–PD-1 therapy on cisplatin-induced ototoxicity and nephrotoxicity has not been established. Here we use a murine model of cisplatin-induced hearing loss to investigate the impact of anti–PD-1 immunotherapy on auditory brainstem responses (ABRs), distortion product otoacoustic emissions (DPOAEs), serum creatinine, and hair cell and renal histology. We demonstrate only mild worsening of DPOAEs at 14.4 and 16 kHz as well as a mild increase in serum creatinine. Renal and hair cell histology as well as ABR measures were unchanged by PD-1 inhibition. Thus, our data suggest that the use of PD-1 inhibition in conjunction with cisplatin results in toxicities that are similar to those of cisplatin alone.

Original languageEnglish (US)
JournalOtolaryngology - Head and Neck Surgery (United States)
DOIs
StateAccepted/In press - Mar 1 2018

Fingerprint

Cisplatin
Brain Stem Auditory Evoked Potentials
Creatinine
Histology
Kidney
Serum
Hearing Loss
Immunotherapy
Clinical Trials
Drug Therapy
Therapeutics

Keywords

  • cisplatin chemotherapy
  • nephrotoxicity
  • ototoxicity
  • PD-1

ASJC Scopus subject areas

  • Surgery
  • Otorhinolaryngology

Cite this

PD-1 Inhibition Minimally Affects Cisplatin-Induced Toxicities in a Murine Model. / Spielbauer, Katie; Cunningham, Lisa; Schmitt, Nicole.

In: Otolaryngology - Head and Neck Surgery (United States), 01.03.2018.

Research output: Contribution to journalArticle

@article{3c3542e85cc249d19ab07c228fa8440f,
title = "PD-1 Inhibition Minimally Affects Cisplatin-Induced Toxicities in a Murine Model",
abstract = "Immune checkpoint inhibition used in combination with standard cisplatin-based chemotherapy regimens is currently under evaluation in clinical trials for head and neck squamous cell carcinoma (HNSCC). The impact of anti–PD-1 therapy on cisplatin-induced ototoxicity and nephrotoxicity has not been established. Here we use a murine model of cisplatin-induced hearing loss to investigate the impact of anti–PD-1 immunotherapy on auditory brainstem responses (ABRs), distortion product otoacoustic emissions (DPOAEs), serum creatinine, and hair cell and renal histology. We demonstrate only mild worsening of DPOAEs at 14.4 and 16 kHz as well as a mild increase in serum creatinine. Renal and hair cell histology as well as ABR measures were unchanged by PD-1 inhibition. Thus, our data suggest that the use of PD-1 inhibition in conjunction with cisplatin results in toxicities that are similar to those of cisplatin alone.",
keywords = "cisplatin chemotherapy, nephrotoxicity, ototoxicity, PD-1",
author = "Katie Spielbauer and Lisa Cunningham and Nicole Schmitt",
year = "2018",
month = "3",
day = "1",
doi = "10.1177/0194599818767621",
language = "English (US)",
journal = "Otolaryngology - Head and Neck Surgery",
issn = "0194-5998",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - PD-1 Inhibition Minimally Affects Cisplatin-Induced Toxicities in a Murine Model

AU - Spielbauer, Katie

AU - Cunningham, Lisa

AU - Schmitt, Nicole

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Immune checkpoint inhibition used in combination with standard cisplatin-based chemotherapy regimens is currently under evaluation in clinical trials for head and neck squamous cell carcinoma (HNSCC). The impact of anti–PD-1 therapy on cisplatin-induced ototoxicity and nephrotoxicity has not been established. Here we use a murine model of cisplatin-induced hearing loss to investigate the impact of anti–PD-1 immunotherapy on auditory brainstem responses (ABRs), distortion product otoacoustic emissions (DPOAEs), serum creatinine, and hair cell and renal histology. We demonstrate only mild worsening of DPOAEs at 14.4 and 16 kHz as well as a mild increase in serum creatinine. Renal and hair cell histology as well as ABR measures were unchanged by PD-1 inhibition. Thus, our data suggest that the use of PD-1 inhibition in conjunction with cisplatin results in toxicities that are similar to those of cisplatin alone.

AB - Immune checkpoint inhibition used in combination with standard cisplatin-based chemotherapy regimens is currently under evaluation in clinical trials for head and neck squamous cell carcinoma (HNSCC). The impact of anti–PD-1 therapy on cisplatin-induced ototoxicity and nephrotoxicity has not been established. Here we use a murine model of cisplatin-induced hearing loss to investigate the impact of anti–PD-1 immunotherapy on auditory brainstem responses (ABRs), distortion product otoacoustic emissions (DPOAEs), serum creatinine, and hair cell and renal histology. We demonstrate only mild worsening of DPOAEs at 14.4 and 16 kHz as well as a mild increase in serum creatinine. Renal and hair cell histology as well as ABR measures were unchanged by PD-1 inhibition. Thus, our data suggest that the use of PD-1 inhibition in conjunction with cisplatin results in toxicities that are similar to those of cisplatin alone.

KW - cisplatin chemotherapy

KW - nephrotoxicity

KW - ototoxicity

KW - PD-1

UR - http://www.scopus.com/inward/record.url?scp=85045326730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045326730&partnerID=8YFLogxK

U2 - 10.1177/0194599818767621

DO - 10.1177/0194599818767621

M3 - Article

JO - Otolaryngology - Head and Neck Surgery

JF - Otolaryngology - Head and Neck Surgery

SN - 0194-5998

ER -